12^th Emirates Oncology Conference 2024 - Abstract Submission Guidelines

Abstract Guidelines:
Abstract content must meet the following guidelines:

• Should address clinically relevant scientific questions as per the below mentioned categories.
• Original scientific data in the form of a randomized clinical trials or prospective or retrospective research studies that have not been presented or published previously.
• High-impact research with practice-changing implications.
• Case reports or series will not be accepted.

Submission Categories:

Important Details:

• The abstract must have the following sections - Introduction, Objectives, Materials and Methods, Results, and Conclusions.
• The abstract must not be more than 400 words and must be based on the original research that has not been published or presented previously.
• Covering letter with a statement defining the purpose of the work to be presented at EOC 2024.
• Five or six keywords relating to the topic should be supplied along with the abstract.
• EOC 2024 Scientific committee will evaluate the content of each abstract and the final selection will be made by international peer review. All accepted abstracts will be published in a peer-reviewed journal. Selected abstracts will be offered an opportunity for oral presentation on 15th November as part of the conference agenda. 
• The organizers will inform the first author about the result of his/her submitted work.
• The deadline for Abstract Submission is extended until October 26, 2024. No abstracts will be accepted after the deadline.
• For any withdrawals, the presenter should notify the organizer in writing at least 7 days prior to the event.
• The presentation must cover the same material as the abstract. Any update to the original abstract must be declared to the scientific committee during final submission.
• The first author should present his/her abstract in the EOC 2024 programme IF IT IS SELECTED for presentation as oral presentation OR Poster. If the first author is unavailable for any reason he/she may nominate a co-author (with similar eligibility criteria) to present the abstract in his/her place provided that the replacement presenter is also a listed co-author and the organising committee is informed of this prior at least 14 days prior to the event. All presenters need a speaker permit prior to the event and this is an essential requirement.  
• The requirements for the first author are as follows-
  1. Should NOT be in a consultant/professor/ or any leadership position.
  2. Should NOT be in a senior nursing or any leadership position.
  3. Trainees/ medical officers/ specialists/ researchers/ medical students are encouraged to submit abstracts as first authors.
• Abstract presentations are meant to encourage trainees and juniors to present oncology related topics with support from senior mentors. Single author submissions are discouraged. 

JIPO REQUIRED INSTRUCTIONS & GUIDELINES FOR APPROVED E-POSTER PRESENTATIONS:

• FORMAT: All abstracts must be prepared and submitted according to the following guidelines:
  • LENGTH: Abstracts should be a maximum 400 words including the title, author information, and text. NOTE: If submitted as a poster, the image will be reduced to fit on one page.
  • AUTHORS: Include the full name of each author in the desired order. Use superscript numbers to indicate each authors’ affiliation. Do not include professional titles or degrees.The submitting author should not add other co-authors without their prior agreement. Do not include anyone who does not meet the criteria for authorship as defined by the ICMJE
    (see http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html).
  • AFFILIATIONS: Number each affiliation and include the department (if applicable), institution or company name, city, state (if applicable), and country.
  • EMAIL: The submitting author must provide a valid email address in case there are any queries following submission of the abstract.
• STRUCTURE: Research abstracts should be a brief structured summary of the paper with headings for the Introduction, Methods, Results, and Conclusion. Key learning points and practice-changing findings of the study or main expected implications are expected.
  • Case reports and series will not be accepted.
  • TEXT: Abstracts must be written in English. Abbreviations should be defined at first mention. Avoid including information that requires a citation or reference.
  • TABLES/FIGURES: 1-2 brief tables or figures (high resolution image file, 300 dpi) are allowed. Tables/figures may be removed if needed due to space constraints. Use of third-party material is not permitted.
  • PROOFREAD: Abstracts will be published as-is. Carefully proofread the submission prior to submitting.
• RESPONSIBILITY: All authors approve the final version of the abstract to be submitted for publication AND agree to be accountable for all aspects of the work.
• PERMISSION TO PUBLISH: By submitting this abstract, the authors give permission to the Journal of Immunotherapy and Precision Oncology (JIPO) to publish the content.
• COPYRIGHTS: Authors attest that their abstract does not include any copyrighted material. Authors attest that the abstract has not been submitted elsewhere and is not under consideration with any other conference. Accepted abstracts will be published as-is in the Journal and are therefore embargoed until the date of presentation or publication, whichever comes first. Thereafter, the authors are permitted to reuse their abstract in the full publication of their work in JIPO or elsewhere.
• QUESTIONS: If you have any additional queries regarding publication (after acceptance), please contact the Journal at: editor@innovationsjournals.com

Restrictions:

• Please do not include audio/video files in your presentation.
• Do not include hyperlinks as there will be no internet access on the e-poster screens.

KEY DATES:
Submission of Abstracts Closes - October 26, 2024 
Abstract Review Process – October 26- 31, 2024 
Acceptance Communication – October 26 - November 3, 2024
Final Submission of Abstract Poster - November 8, 2024 

For any inquiries regarding abstract submissions please reach out to Eugene Pabustan at eugene.pabustan@index.ae